The novel selective aldosterone synthase inhibitor BI 690517 (up to 10 mg daily) with concurrent renin-angiotensin-system (RAS) inhibition, with or without the SGLT2 inhibitor empagliflozin, dose ...

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in ...

The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis.

Furthermore, dehydration disrupts the Renin-Angiotensin-Aldosterone System (RAAS), a critical hormonal pathway involved in regulating blood pressure and fluid balance.